Abstract
AbstractThe preparation of multinuclear metal complexes offers a route to novel anticancer agents and delivery systems. The potency of a novel triangular multinuclear complex containing three platinum atoms, Pt‐3, towards breast cancer stem cells (CSCs) is reported. The trinuclear platinum(II) complex, Pt‐3 exhibits selective toxicity towards breast CSCs over bulk breast cancer cells and non‐tumorigenic breast cells. Remarkably, Pt‐3 inhibits the formation, size, and viability of mammospheres to a better extent than salinomycin, an established CSC‐potent agent, and cisplatin and carboplatin, clinically used platinum drugs. Mechanism of action studies show that Pt‐3 effectively enters breast CSCs, penetrates the nucleus, induces genomic DNA damage, and prompts caspase‐dependent apoptosis. To the best of our knowledge, Pt‐3 is the first multinuclear platinum complex to selectively kill breast CSCs over other breast cell types.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have